Xeltis is a company.
Xeltis has raised $45.0M across 2 funding rounds.
Key people at Xeltis.
Xeltis has raised $45.0M in total across 2 funding rounds.
Xeltis is a medtech company developing transformative vascular implants using proprietary Endogenous Tissue Restoration (ETR) technology, which enables patients' own tissue to replace artificial vessels and valves, reducing complications like thrombosis, stenosis, infection, and the need for repeat surgeries.[1][2][4] Its lead product, aXess, is an implantable blood vessel for hemodialysis vascular access, targeting patients with chronic kidney disease requiring dialysis, while the platform extends to coronary bypass, pulmonary heart valves, and peripheral arterial disease.[1][2][3] Xeltis serves healthcare providers and patients undergoing vascular surgeries, addressing limitations of current synthetic grafts and valves that often fail prematurely.[1][2] The company, founded in 2006 and headquartered in Eindhoven, Netherlands, with operations in Europe and the US, has raised significant funding—including nearly €50 million from the European Investment Bank and shareholders in recent years—showing strong growth momentum toward commercialization.[1][2][3]
Xeltis emerged as a university spin-off around 2006 in the Netherlands, combining interdisciplinary expertise in biochemistry, medicine, and engineering to pioneer regenerative implants.[1][6] The idea stemmed from Nobel prize-winning breakthroughs in bio-absorbable polymer technology, leading to the ETR platform that leverages the body's natural healing to create living vessels and valves.[2][6][9] Early pivotal moments included shifting focus from initial cardiac valve concepts to scalable vascular applications like hemodialysis access, supported by long-term investors such as EQT Life Sciences, Kurma Partners, Ysios Capital, DaVita Venture Group, and the European Innovation Council, which enabled clinical trials without short-term exit pressures.[1][6] By 2011, under sustained leadership, Xeltis evolved from a small research entity into a leading medtech innovator, with encouraging preliminary data from ongoing aXess studies driving further investment.[3][6]
Xeltis rides the regenerative medicine wave, a frontier in medtech aiming to repair tissues via the body's own mechanisms, aligning with trends in personalized, durable implants amid rising chronic diseases like kidney failure (affecting 1.7 million in the Netherlands alone).[3][6][7] Timing is ideal as aging populations and dialysis demands grow—millions worldwide need better vascular solutions—while market forces favor cost-saving innovations reducing reinterventions and healthcare burdens, supporting SDG 3 (good health and well-being).[2][3] Xeltis influences the ecosystem as a frontrunner, pioneering ETR to shift standards from synthetic failures to living tissues, inspiring scalable biotech and attracting public-private funding like EIB loans.[1][3][6]
Xeltis is poised for commercialization of aXess post-ongoing trials, with €50 million funding accelerating market entry and expansion to pulmonary valves and other indications.[2][3] Trends like AI-driven medtech, sustainability in implants, and global dialysis growth will propel it, potentially slashing long-term costs and transforming pediatric cardiology.[2][4][6] Its influence may evolve from innovator to category leader, redefining vascular care as regenerative standards prevail—echoing its founding ambition to elevate outcomes for millions in surgery-dependent therapies.[1][2]
Key people at Xeltis.
Xeltis has raised $45.0M in total across 2 funding rounds.
Xeltis's investors include EQT Life Sciences.
Xeltis has raised $45.0M across 2 funding rounds. Most recently, it raised $12.0M Series D in September 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2019 | $12.0M Series D | EQT Life Sciences | |
| Dec 1, 2014 | $33.0M Series B | EQT Life Sciences |
